Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myelodysplastic-Myeloproliferative Diseases × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Specimen Handling 7 Biopsy 6 ruxolitinib 2 fludarabine 2 decitabine and cedazuridine drug combination 2 Azacitidine 2 venetoclax 1 veliparib 1 posaconazole 1 peginterferon alfa-2b 1 onvansertib 1 merphos 1 iadademstat 1 fedratinib 1 axatilimab 1 Topotecan 1 Tacrolimus 1 Succimer 1 Stem Cell Transplantation 1 Pentetic Acid 1 Methotrexate 1 Melphalan 1 Janus Kinase Inhibitors 1 Injections 1 Idarubicin 1 High-Energy Shock Waves 1 Granulocyte Colony-Stimulating Factor 1 Geritol 1 Edetic Acid 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡